September 16, 2024
Article
Taletrectinib elicited high and durable overall response rates with favorable tolerability in patients with advanced ROS1-positive NSCLC.
September 10, 2024
Article
Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.
August 08, 2024
Video
Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.
July 02, 2024
Video
Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.
June 02, 2024
Article
Taletrectinib demonstrated high response rates and a tolerable safety profile in patients with ROS1-positive non–small cell lung cancer.